BioNTech SE ADR
Suletud
SektorTervishoid
90.78 -1.14
Ülevaade
Aktsiahinna muutus
24h
Min
88.01
Max
93.55
Sissetulek | -239M -541M |
|---|---|
Müük | -779M 120M |
Aktsiakasum | -1.95 |
Kasumimarginaal | -450.381 |
Töötajad | 7,807 |
EBITDA | -383M -450M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +36.04% upside |
Järgmine tulemuste avaldamine | 3. nov 2026 |
|---|
Turukapital | -1.8B 23B |
|---|---|
Eelmine avamishind | 91.92 |
Eelmine sulgemishind | 90.78 |
BioNTech SE ADR Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
BioNTech SE ADR Prognoos
Hinnasiht
By TipRanks
36.04% tõus
12 kuu keskmine prognoos
Keskmine 125.5 USD 36.04%
Kõrge 158 USD
Madal 94 USD
Põhineb 12 Wall Streeti analüütiku instrumendi BioNTech SE ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest BioNTech SE ADR
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
